Exploring the antioxidant properties of semaglutide: A comprehensive review.
J Diabetes Complications · 2024
Last updated 2026-05-28Semaglutide is a GLP-1 drug used to treat diabetes that may also help reduce oxidative stress, a harmful process linked to diabetes complications. Studies suggest it has antioxidant effects, but researchers are still investigating how it works and how strong these effects are.
AI summary of the abstract below.
| Journal | J Diabetes Complications, 2024 |
|---|---|
| Citations | 7 |
| Relative citation ratio | 1.86 |
| NIH percentile | 71 |
| Molecules | semaglutide |
Abstract
Patients with diabetes commonly experience an aberrant production of free radicals and weakened antioxidative defenses, making them highly susceptible to oxidative stress development. This, in turn, can induce and promote diabetic complications. Therefore, utilizing antidiabetic agents with antioxidative properties can offer dual benefits by addressing hyperglycemia and reducing oxidative damage. Semaglutide, a recently approved oral form of glucagon-like peptide-1 (GLP-1) analogues, has shown potent antidiabetic effects. Additionally, recent studies have suggested that it possesses antioxidative properties. However, the exact effects and the molecular pathways involved are not well understood. In this review, we present the latest findings on the antioxidative impacts of semaglutide and draw conclusions about the mechanisms involved.
Verbatim abstract via PubMed 39549371 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.